BridgeBio Pharma Inc

1BBIO

Company Profile

  • Business description

    BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

  • Contact

    3160 Porter Drive
    Suite 250
    Palo AltoCA94304
    USA

    T: +1 650 391-9740

    https://www.bridgebio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    730

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,794.6527.940.36%
DAX 4024,275.3268.410.28%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,868.3114.130.16%
HKSE23,876.70271.37-1.12%
NASDAQ20,418.465.950.03%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers